-
12:26:06 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

EGRX Stock News

01/05/22 1:39 PM
Nasdaq : EGRX
low float
Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin
Eagle Pharmaceuticals, Inc. today provided a business update for 2022:. This is an important product for Eagle, as Vasostrict ® U.S. sales totaled $890 million for the LTM ended September 30, 2021. PEMFEXY™: On February 1, 2022, the Company will launch PEMFEXY, a ready-to-use liquid with a unique J-code. Eagle has been building inventory and believes this is a...
RHEA-AI
very positive
01/03/22 4:30 PM
Nasdaq : EGRX
conferenceslow float
Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present virtually at the 40 th Annual J.P. Morgan Healthcare Conference as follows:. The webcast of the presentation will be accessible for 30 days thereafter, via the Company’ s website at www.eagleus.com, under...
RHEA-AI
neutral
12/29/21 11:24 AM
Nasdaq : EGRX
low float
Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin
Eagle Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has determined that the Company has maintained its 180 days of marketing exclusivity for its recently approved abbreviated new drug application for vasopressin. In August, the U.S. District Court for the District of Delaware held that Eagle’ s proposed vasopressin...
RHEA-AI
neutral
12/20/21 11:39 AM
Nasdaq : EGRX
low float
Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin
Eagle Pharmaceuticals, Inc. today announced that Par Pharmaceutical, Inc. has unilaterally withdrawn its request that the U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’ s recently approved vasopressin product. Par’ s appeal of the District Court’ s ruling on...
RHEA-AI
neutral
11/22/21 6:50 AM
Nasdaq : EGRX
conferenceslow float
Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present virtually at the Piper Sandler 33 rd Annual Healthcare Conference 2021 as follows:. Eagle will be participating in 1 x1 meetings on December 1. Investor Relations for Eagle Pharmaceuticals, Inc.: Lisa M. Wilson In-Site...
RHEA-AI
neutral
10/28/21 5:05 PM
Nasdaq : EGRX
conferencesearningslow float
Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021
Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2021 third quarter financial results on Tuesday, November 9, 2021, before the market opens. Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:. Investor Relations for Eagle Pharmaceuticals,...
RHEA-AI
neutral
09/07/21 6:50 AM
Nasdaq : EGRX
conferenceslow float
Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021
Eagle Pharmaceuticals, Inc. will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashin, Chief Medical Officer, and will feature other guest speakers, to discuss the CAL02 opportunity, the current treatment landscape and the unmet medical need in treating patients with severe pneumonia as follows:. A replay of the conference...
RHEA-AI
neutral